Coronary Stenosis clinical trials at UCLA
1 in progress, 0 open to eligible people
Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Sorry, in progress, not accepting new patients
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major atherosclerotic cardiovascular disease (ASCVD) event will significantly reduce the risk of 4-Point-Major Adverse Cardiovascular Events (4P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, and urgent coronary revascularization, compared to placebo.
Torrance 5403022, California 5332921 and other locations
Last updated: